Understand the Nuance
Published loading...Updated

Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial

Summary by Ground News
Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday. The company released data from a late-stage study of Filspari in IgA nephropathy. In a head-to-head study versus irbesartan, FilsPari fell short of producing a statistically significant difference by one measure of kidney function.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

MarketWatch broke the news in United States on Thursday, September 21, 2023.
Sources are mostly out of (0)